乳腺浸润性导管癌干细胞标志物ALDH1、CD133与肿瘤血管生成相关性

目的 探讨乳腺浸润性导管癌干细胞标志物乙醛脱氢酶1(aldehyde dehydrogenase1,ALDH1)、细胞分化标志133(cluster of differentiation 133,CD133)与肿瘤血管生成的相关性.方法 收集颈胸外科肿瘤手术切除乳腺癌标本95例,所选标本均经病理确诊为乳腺浸润性导管癌,采用免疫组织化学双染法检测所选标本中ALDH1、CD133干细胞样细胞,并应用免疫组织化学单染法检测其肿瘤血管性标志CD4、CD105及血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)的表达情况,分析ALDH1、CD133与肿瘤血管生成的相关性.结果 95例乳腺浸润性导管癌组织中存在8例(8.3％) ALDH1 +/CD133+表型,ALDH1 +/CD133+表型与ER、VEGF表达以及肿瘤血管生成指标CD34 MVD、CD105 MVD均有相关性(均P<0.05).结论 ALDH1、CD133可作为乳腺肿瘤细胞的特异性标志物,其中ALDH1 +/CD133+表型干细胞可以促进肿瘤新生血管的生成.     

CD44+ CD24-/low与ALDH1+在乳腺癌组织中的表达及其意义

乳腺癌是妇女常见的恶性肿瘤。近年的研究发现在恶性肿瘤中存在一种亚群细胞,其恶性程度高于一般的肿瘤细胞。如果分离得到乳腺癌干细胞,就可以通过其表面特异的标志物或异常表达的标志物,检测体内是否残留有肿瘤干细胞,同时把乳腺癌干细胞作为靶细胞,建立乳腺癌干细胞模型,为乳腺癌研究奠定细胞学基础,进而指导手术、放化疗及分子靶向治     

双特异性CAR-T细胞对EGFRvⅢ+/CD133+胶质瘤干细胞的靶向杀伤

目的：制备双特异性CAR-T(bs CAR-T)细胞,观察其对表达表皮生长因子Ⅲ型突变阳性(EGFRvⅢ⁺,简称vⅢ⁺)和CD133+胶质瘤干细胞的靶向杀伤作用。方法：基于前期研制的vⅢ/CD133双特异性微抗体和二代CAR构建的双特异性CAR(bs CAR),制备慢病毒载体转染人外周血T细胞,FCM和WB法检测bs CAR转染效率和表达水平。bs CAR-T细胞和vⅢ⁺/CD133⁺U87胶质瘤干细胞共培养,乳酸脱氢酶(LDH)释放实验、IFN-γ分泌实验检测其特异性杀伤作用和对IFN-γ分泌的促进作用。制备裸鼠vⅢ+/CD133+U87干细胞移植瘤模型检测bs CAR-T细胞对移植瘤生长的抑制作用。结果：vⅢsc Fv和CD133sc Fv通过重叠PCR无缝连接入二代CAR表达框(S-vⅢscFv/CD133scFv-Hinge-TM-CD137-CD3ζ)中,然后克隆入p CDH-MSCV-MCS-EF1-copGFP载体的Eco RⅠ和Bam HⅠ位点(pbs CAR)。3种质粒(p VSV...     

肿瘤干细胞及其与CD133的关系

越来越多的证据支持肿瘤干细胞理论,肿瘤可以认为是一个被少数肿瘤干细胞驱动的异常器官,它们具有自我更新和多向分化潜能.CD133在许多肿瘤中相继被报道,尽管其生物学功能还不清楚,但目前已经是一个非常有价值的分选肿瘤干细胞的标志,研究发现CD133+肿瘤细胞与肿瘤发生、侵袭、转移、耐药及复发有着密切的关系,因此深入了解CD133+肿瘤细胞的分子生物学特性对寻求有效的抗癌治疗,特别是靶向肿瘤干细胞的治疗是相当必要的.     

乳腺浸润性导管癌组织中环氧合酶-2的表达与细胞增生和血管生成的关系

目的 探讨环氧合酶-2(COX-2)蛋白在乳腺浸润性导管癌组织中的表达及其与细胞增生和微血管密度(MVD)的关系.方法 应用免疫组织化学法检测52例乳腺浸润性导管癌组织中COX-2和Ki-67蛋白的表达情况,用CD34抗体标记乳腺癌血管内皮细胞,计算MVD.结果 乳腺浸润性导管癌组织中COX-2蛋白的阳性表达率为57.7%,COX-2阳性组Ki-67指数为(56.07±17.37)%,COX-2阴性组Ki-67指数为(27.32±16.28)%,COX-2阳性组MVD为32.46±12.59,COX-2阴性组MVD为25.04±10.48,COX-2阳性组Ki-67、MVD显著高于COX-2阴性组(P＜0.05).结论 乳腺浸润性导管癌组织中COX-2蛋白高表达,COX-2可促进肿瘤细胞增生和肿瘤肿瘤血管生成,从而成为促进乳腺癌浸润、转移的途径之一.     

CD133与肿瘤干细胞研究进展

越来越多的证据表明肿瘤中存在肿瘤干细胞(cancer stem cells),并且其与肿瘤的增殖、转移、复发和对放化疗不敏感关系密切.因此,肿瘤治疗应当针对肿瘤干细胞,通过特异表面标记分选肿瘤干细胞是研究其生长特点的前提.近年来,CD133为研究最多的在于细胞(stem cell)和多种组织肿瘤干细胞表面独立表达的特异标记分子.通过CD133可以分选干细胞、前体细胞和肿瘤干细胞.众多研究表明,CD133~+肿瘤细胞与肿瘤的自我更新、分化潜能、信号传导调控、药物耐受、复发和预后等均有相关性.CD133~+细胞有望在干细胞相关疾病的治疗和肿瘤靶向治疗中发挥巨大作用.     

肝细胞性肝癌组织CD133+细胞肿瘤干细胞特性的研究

目的 越来越多的研究表明,肝癌细胞系中能检测到肿瘤干细胞(cancer stem cells,CSCs)的存在.本研究旨在探讨从肝细胞性肝癌(hepatocellular carcinoma,HCC)组织样本中分离获得的CD133+细胞是否具有CSCs特性.方法 将2014-02-01-2015-06-30广西医科大学附属肿瘤医院肝胆外科25例手术获得的新鲜HCC组织和对应癌旁组织,采用酶消化法分别消化成单个肝癌细胞和单个肝细胞,利用流式细胞术检测部分单个肝癌细胞和单个肝细胞CD133的表达率.用剩余的单个肝癌细胞进行原代培养,流式细胞术将培养获得的肝癌细胞分选为CD133+和CD133-细胞,通过平板克隆形成实验、肿瘤球形成实验和裸鼠移植瘤形成实验对比分析这两组细胞的CSCs特性.结果 25例HCC组织中CD133的表达率为3.8％～8.3％,平均值为(5.8±1.6)％,而癌旁组织CD133的表达率为0.1％～0.4％,平均值为(0.2±0.1)％,两者比较差异有统计学意义,t=17.12,P＜0.001.CD133+和CD133-细胞的平均克隆率分别为(25.2±0.8)％和(7.6±0.8)％,两者比较差异有统计学意义,t=81.95,P＜0.001.CD133+和CD133-细胞的平均成球率分别为(20.3±0.6)％和(12.5±1.4)％,两者比较差异有统计学意义,t=68.17,P＜0.001.CD133+细胞的裸鼠移植瘤形成能力明显高于CD133-细胞.结论 从HCC组织样本中分离获得的CD133+细胞具有明显的CSCs特性.     

CD133+细胞在乳腺良恶性病变中的分布特点及其临床病理意义

研究CD133+细胞在乳腺普通型增生、乳腺不典型增生、乳腺原位癌、浸润性乳腺癌中的分布特点及其与乳腺癌临床病理特征的关系。方法:采用免疫组织化学方法对45例正常乳腺组织、41例普通型增生乳腺组织、39例不典型增生乳腺组织、51例乳腺原位癌组织、121例乳腺癌组织中CD133+的表达进行检测,分析CD133+细胞在乳腺良恶性病变中的分布特点。结果:CD133+在正常乳腺组织中不表达,在乳腺普通型增生、不典型增生、原位癌、浸润性癌的表达率逐渐增高,分别为31.7%（13/41）、48.7%（19/39）、64.7%（33/51）、74.4%（90/121）,有显著性差异（P<0.01）。CD133+的表达率随乳腺癌组织学分级［Ⅰ级63.6%（21/33）、Ⅱ级72.2%（26/36）、Ⅲ级82.7%（43/52）,P<0.05］和TNM分期［Ⅰ期57.1%（12/21）、Ⅱ期69.4%（34/49）、Ⅲ期68.7%（11/16）、Ⅳ期94.3%（33/35）,P<0.001］的增高而增高;有淋巴结转移或远处转移者分别高于无转移者、无远处转移者（P<0.05）;有复发者高于无复发者（P<0.05）;与患者年龄、月经状态、肿瘤的组织学类型、肿瘤大小、ER、PR、Her-2的表达无显著相关（P>0.05）。结论:CD133+细胞可能在乳腺增生与癌变过程中起重要作用;CD133+的乳腺癌细胞与乳腺癌的侵袭、转移和复发密切相关,CD133+是提示乳腺癌恶性程度和预后的指标之一。      

CD133/prominin-1与胃肠道肿瘤的研究进展

目的:探讨CD133/prominin-1在胃肠道肿瘤患者中的表达情况及其在肿瘤诊断治疗中的意义。方法:应用PubMed及CHKI期刊全文数据库检索系统,以胃癌、结肠癌、直肠癌、胃肠道肿瘤和CD133等为关键词,检索1989-01-2009-10的相关文献,共检索到英文文献1 071条,中文文献79条。纳入标准:1)CD133/prominin-1的基本资料介绍。2)CD133/prominin-1在正常胃肠道中的表达研究。3)CD133/promi-nin-1在胃肠道肿瘤患者体内表达、与临床病理和预后关系的研究。4)CD133/promi-nin-1与胃肠道肿瘤干细胞的关系及在肿瘤诊治中的应用研究。根据纳入的标准,精选了55篇文献,最后纳入了33篇文献进行分析综述。结果:CD133/prominin-1是一个含有5个跨膜区域的单链糖蛋白,主要在干细胞、祖细胞和肿瘤干细胞表达,一直被作为分离和鉴定这些细胞的标志。胃肠道中的正常组织和肿瘤组织中均有CD133的表达,胃肠道肿瘤中的CD133表达与肿瘤干细胞、临床病理和预后有关。结论:了解CD133在胃肠道肿瘤中的表达,可以加深我们对胃肠道肿瘤发生发展机制的认识,...     

人类白细胞分化抗原133与乳腺浸润性导管癌临床病理特征的关系

目的 研究肿瘤干细胞标志物人类白细胞分化抗原（CD）133在乳腺浸润性导管癌组织中的表达及其与临床病理因素之间的关系.方法 收集2001年1月至2005年12月间承德市肿瘤医院和承德医学院附属医院肿瘤科的102例乳腺浸润性导管癌组织,采用免疫组织化学方法检测其CD133蛋白表达,并用χ^2验或Fisher确切概率法分析CD133表达与临床病理因素的关系.结果 乳腺浸润性导管癌组织不同程度地表达CD133.不同肿瘤直径组间CD133阳性表达率差异有统计学意义（χ^2=7.476,P=0.024）,其中肿瘤直径〉2～5 cm组CD133阳性表达率明显高于肿瘤直径≤2 cm组[56.72%（38/67）比26.09%（6/23）,χ^26.429,P＆lt;0.012].不同组织学分级间相比,CD133阳性表达率的差异也有统计学意义（χ^26.274,P=0.043）.并且,有淋巴结转移者CD133阳性表达率比无淋巴转移者高[64.71%（22/34）比39.71%（27/68）,χ^25.675,P=0.017）].乳腺浸润性导管癌组织中,CD133阳性表达率在不同年龄、不同临床分期之间差异无统计学意义（χ^20.177,P=0.674;χ^22.874,P=0.242）.结论 CD133有可能作为判断乳腺浸润性导管癌侵袭转移的指标.     

Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma

Background: Biomarkers in breast neoplasms provide invaluable information regarding prognosis and help determining the optimal treatment. We investigated the possible correlation between cancer stem cell (CSC) markers (CD133, and ALDH1) in invasive ductal breast carcinomas with some clinicopathological parameters. Aim: To assess the correlation between expression of cancer stem cell (CSC) markers (CD133, and ALDH1) and clinicopathological parameters of invasive ductal breast carcinomas. Materials and Methods: Immunohistochemical analysis of CD133 and ALDH1 was performed on a series of 120 modified radical mastectomy (MRM) specimens diagnosed as invasive ductal breast carcinoma. Results: Expression of both CD133 and ALDH1 was significantly changed and related to tumor size, tumor stage (TNM), and lymph node metastasis. A negative correlation between CD133 and ALDH1 was found. Conclusions: Detecting the expression of CD133 and ALDH1 in invasive ductal breast carcinomas may be of help in more accurately predicting the aggressive properties and determining the optimal treatment.     

Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer

Purpose

CD133 and aldehyde dehydrogenase 1 (ALDH1) expression are reliable poor-prognosis markers associated with the presence of adverse biomarkers and subtypes of breast cancer. The aim of our study was to investigate and compare the clinical impact of CD133 and ALDH1 expression in invasive breast cancer.

Methods

A total of 291 consecutive patients with invasive breast cancer who underwent breast cancer operations from 2005 to 2010 at a single institution were included in this retrospective review. CD133 and ALDH1 expression were determined by immunohistochemistry.

Results

CD133 and ALDH1 expression were positive in 24.7% and 22.0% of the patients, respectively, and were associated with tumor size, cancer stage, estrogen receptor negativity, nonluminal subtype, triple-negative breast cancer, and recurrence. CD133 expression was significantly associated with lymph node metastasis, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, chemotherapy, and poor disease-free (p=0.002) and overall survival (p=0.014), but ALDH1 expression was not. Cancer stage (p<0.001) was an independent prognostic factor for disease-free survival in multivariate analysis. Cancer stage (p<0.001) and receipt of radiotherapy (p=0.045) were independent prognostic factors for overall survival in multivariate analysis.

Conclusion

CD133 or the combination of CD133 and ALDH1 expression were more widely associated with the presence of adverse biomarkers and subtypes of breast cancer, compared to ALDH1 expression alone, and these markers may have a potential predictive role and be a helpful tool in the management for patients with invasive breast cancer.     

Expression of CD 133 in Invasive Ductal Carcinoma of Breast

Background: CD133 is a commonly used cancer stem cell (CSC) marker in breast cancer. However, the association between CD133 expression, with clinicopathological features and prognosis in breast cancer, is poorly understood in the Indian subcontinent. This study was designed to explore the expression of CD 133 in breast carcinoma and to know its association  between CD133 and clinicopathological characteristics. Methods: A total of fifty seven cases were included in the study. All the clinicopathological parameters were collected from Department of Pathology archives. Slides, blocks, clinical information, tumor size and axillary lymph node status were obtained from medical records and the pathology reports. Immunohistochemistry was done using CD 133 antibodies. Both Cytoplasmic and membranous staining was taken a positive. Scoring was done based on percentage of positive cells and intensity of staining. MS Excel, SPSS version 22 (IBM SPSS Statistics, Somers NY, USA) was used to analyze data.p value < 0.05 was considered as statistically significant. Results: Statistically significant association between the CD 133 expression and nodal metastasis, tumor stage and Nottingham prognostic index was analysed. There was no statistical correlation between CD 133 expression age, tumor grade and tumor size. The disease free survival showed the mean disease free survival of CD 133 positivity cases was 16months. And the patients who were negative for CD 133 expression had mean survival of 30 months. By the Kaplan Mayer graph it was evident that the more the CD 133 expression the lesser was the disease free survival of the patients. Conclusion: CD 133 expression was seen in 77.08% cases and was associated with tumor stage, lymph node metastasis, poor Nottingham prognostic index and  worse disease free survival. An increasing trend of association was seen between CD 133 expression and Age, Tumor Size and Tumor grade.     

ER阴性乳腺癌高表达乳腺癌干细胞标志物乙醛脱氢酶1

目的探讨85例乳腺浸润性导管癌中肿瘤干细胞标志物乙醛脱氢酶1(ALDH1)的表达情况及与临床病理特征的关系。方法采用免疫组化法检测乳腺组织芯片85例乳腺浸润性导管癌组织中ALDH1的表达并分析其临床意义。结果 ALDH1在雌激素受体(ER)阴性的乳腺癌中表达率(34.6%)显著高于ER阳性者(12.1%;P=0.024)。不同亚型乳腺癌中存在ALDH1表达的显著差异,其中三阴性乳腺癌中ALDH1的表达较高(50.0%,P=0.034)。ALDH1的表达在不同大小肿块的肿瘤中也存在差异,其中肿块小于2 cm的乳腺癌中ALDH1的表达率最高(50.0%;P=0.040)。而ALDH1的表达与患者年龄、肿瘤分级、淋巴结转移、疾病分期及PR、HER-2状态无关(P>0.05)。结论 ER阴性乳腺癌尤其是三阴性乳腺癌中ALDH1的表达率较高,提示ER阴性乳腺癌中存在较高比例的干细胞,进而有助于更好地理解其预后差的特点。     

CD147和MMP-9在乳腺浸润性导管癌中的表达及其相关性

目的探讨CD147和MMP-9蛋白在乳腺癌及其周围正常组织中的表达及两者的相关性。方法采用免疫组织化学法,检测50例乳腺癌及20例癌旁正常组织中CD147和MMP-9蛋白的表达情况。结果乳腺癌组织中CD147的阳性表达率为60%（30/50）,MMP-9的阳性表达率为66%（33/50）,显著高于癌旁组织（P〈0.01）;在乳腺癌组织中CD147、MMP-9蛋白表达之间存在显著正相关（γ=0.630,P〈0.01）。CD147、MMP-9表达与淋巴结转移、TNM分期显著相关（P〈0.05）,与患者年龄、肿瘤大小无明显相关性（P〉0.05）。结论乳腺癌组织中存在CD147、MMP-9的高表达;CD147蛋白可通过诱导MMP-9蛋白的表达上调,促进乳腺癌侵袭、转移。     

Targeting the BRAF Signaling Pathway in CD133pos Cancer Stem Cells of Anaplastic Thyroid Carcinoma

Background: Cancer stem cells (CSCs) with a self-renewal ability in tumor cells population, execute a pivotalfunction in tumorigenesis, retrogression, and metastasis of malignant cancers such as anaplastic thyroid carcinoma(ATC). Materials and Methods: In this study, we isolated CSCs subpopulation with CD133 surface marker fromthree ATC cell lines by magnetic cell sorting assay. After confirming the segregation by the flow cytometry method,BRAF and sodium-iodide symporter (NIS) genes were investigated in them before and after incubation with BRAFinhibitor. Also, we evaluated the NIS protein expression and localization. Results: Established upon q-RT PCR data,when compared to human normal thyrocytes, the BRAFV600E gene was over-expressed in CD133pos cells (>1705.99 ±55.55 fold, Mean ± SEM, n=3, P- value<0.05), whilst the expression of NIS gene was very restricted (< 0.0008 ± 5.43fold, Mean ± SEM, n=3, P- value<0.05) in them. Also, our results showed that BRAF inhibition affected NIS proteinexpression and localization. Conclusions: Current study showed that the differentiate genes/proteins expression canbe induced in the CSCs via focus on signal transduction pathways and targeting their molecules, that are involved inexpression of these genes/proteins. Therefore, attention to targeting CSCs along with routine thyroid cancer therapy,can help to ATC treatment.     

调节性T细胞在口腔鳞癌患者外周血及癌组织中的表达和意义

目的 探讨CD4+CD25+Foxp3+调节性T细胞（regulatory T cell,Treg）在口腔鳞癌患者外周血及癌组织中的表达和意义。方法 选取初诊的30例口腔鳞癌患者,按临床分期分为A、B两组,A组为Ⅰ、Ⅱ期患者,B组为Ⅲ、Ⅳ期患者,10例健康志愿者为对照组（C组）。分别采集三组受试对象晨起空腹外周血3 ml,采用流式细胞术测定外周血中CD4+CD25+Foxp3+调节性T细胞、CD80、CD86和HLA-DR的表达情况;取试验组及对照组手术标本,利用免疫组织化学法测定Foxp3+调节性T细胞的浸润情况。结果 CD4+CD25+Foxp3+T淋巴细胞占CD4+ T淋巴细胞比例在三组中分别为（2.80±0.90）%(A组)、（5.09±1.72）%（B组）、（0.57±0.15）%（C组） , 组间比较差异具有统计学意义（P=0.000）。A、B组外周血中单个核细胞表面共刺激分子CD80+CD86+、 CD80+HLA-DR+及CD86+HLADR+细胞的表达明显低于C组;CD4+CD25+Foxp3+调节性T细胞所占比例与CD80+CD86+、CD80+HLA-DR+和CD86+HLA-DR+表达率进行直线相关分析,相关系数分别为-0.512、-0.430、-0.461,均有统计学意义。免疫组织化学结果显示,Foxp3在口腔鳞癌组织中主要分布在黏膜固有层肿瘤间质,其中Foxp3+调节性T细胞在高分化和中分化口腔鳞癌中少,在低分化口腔鳞癌中多,两者间差异有统计学意义。结论 检测口腔癌患者外周血和肿瘤组织中CD4+CD25+Foxp3+调节性T胞,有助于对机体抗肿瘤免疫水平、病变进展情况和肿瘤预后进行评估,为临床生物治疗提供佐证。     

ALDH1 in Combination with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis in Urothelial Carcinoma of the Urinary Bladder

Background: The aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is one of the promising markersfor identifying cancer stem cells in many cancer types, along with other markers including CD44. The aim ofthe present study was to evaluate the expression and clinical significance of putative cancer stem cell markers,CD44 and ALDH1A1, in a series of urothelial carcinomas of urinary bladder (UCUB) by tissue microarray(TMA). Materials and Methods: A total of 159 Urothelial Carcinomas (UC) including 96 (60%) low gradeand 63 (40%) high grade carcinomas were immunohistochemically examined for the expression of CD44 andALDH1A1. Correlations of the relative expression of these markers with clinicopathological parameters werealso assessed. Results: High level expression of ALDH1A1 was found in 16% (25/159) of bladder UC which wassignificantly correlated with increased tumor size (p value=0.002), high grade (p value<0.001), pathologic stage(T1, p value=0.007 and T2, p value<0.001) and increased rate of recurrence (p value=0.013). A high level of CD44expression was found in 43% (68/159) of cases, being positively correlated with histologic grade (p value=0.032)and recurrence (p value=0.039). Conclusions: Taken together, our results showed that ALDH1 was concurrentlyexpressed in a fraction of CD44+ tumors and its expression correlated with poor prognosis in UCs. ALDH1A1could be an ideal marker for targeted therapy of UCs in combination with conventional therapies, particularlyin patients with high grade carcinomas. These findings indicate that cells expressing ALDH1A1 along with CD44can be a potential therapeutic target in bladder carcinomas.     

Prognostic Value of Cancer Stem Cell Markers CD44 and ALDH1/2 in Gastric Cancer Cases

Purpose: To determine expression levels of CD44 and ALDH1/2, known cancer stem cell (CSC) markers, in stomach adenocarcinomas and assess relationships with clinicopathologic parameters and prognosis. Methods: Eighty patients diagnosed with gastric cancer between the years 2011-2015 were included in this study of clinicopathologic characteristics, postoperative prognostic indexes and stem cell marker CD44 and ALDH1/2 expression in paraffin-embedded tumour sections analyzed immunohistochemically. Clinicopathologic parameters were evaluated using the chi-square test and t-test. Survival analyses were conducted using Kaplan-Meier statistics. Results: We observed positive CD44 and ALDH1/2 staining in 45.0 % and 67.5% of tumour tissues, respectively, but not in normal gastric mucosa. Recurrence-free survival (RFS) was found to be shorter in cases with high levels of CD44 expression (p=0.004). Similarly, short RFS was observed in patients with high levels of CD44 and ALDH1/2 co-expression (p=0.004). Furthermore, tumour invasion depth was found to correlate with high CD44 and ALDH1/2 co-expression (p=0.028). Conclusion: The cancer stem cell markers CD44 and ALDH1/2 may indicate poor patient prognosis and play a role in tumour development and invasion.     

大肠癌组织中Survivin表达与血管生成、细胞增殖的关系

目的　探讨大肠癌组织中Survivin表达与血管生成、细胞增殖的关系。方法　采用原位杂交方法和免疫组织化学方法 ,对 46例大肠癌、2 2例大肠腺瘤和 10例大肠正常组织进行SurvivinmRNA和PCNA检测 ,并计数微血管密度 (MVD)。结果　大肠癌组织中SurvivinmRNA、PCNA指数和MVD均显著高于大肠腺瘤和大肠正常组织 (P <0 .0 5 )。SurvivinmRNA表达阳性组中 ,MVD和PCNA指数均明显高于SurvivinmRNA阴性组 (P <0 .0 5 )。结论　Survivin在大肠癌组织中表达上调 ,并与血管生成和细胞增殖关系密切 ,提示Survivin对大肠癌的发生发展起重要作用